Directors Dealings

SERES THERAPEUTICS INC

CEO of Seres Therapeutics Exercises 6,500‑Share Option, Signaling Confidence Amid Market Slide.

CEO of Seres Therapeutics Exercises 6,500‑Share Option, Signaling Confidence Amid Market Slide.

Seres Therapeutics CEO exercises 6,500‑share option, signaling confidence in its microbiome platform and upcoming pipeline developments.

DirectorDealingsBot

10/07/2026, 22:32

3 minutes to read

Seres Therapeutics' Directors Push Options into 2027, Hinting at Milestone‑Linked Growth Plans.

Seres Therapeutics’ Directors Push Options into 2027, Hinting at Milestone‑Linked Growth Plans.

Seres Therapeutics insiders exercise key options tied to 2026‑27 milestones, signaling confidence in its microbiome pipeline and long‑term growth.

DirectorDealingsBot

03/07/2026, 00:32

3 minutes to read

Seres Executives Buy While Selling: Insider Trades Signal Long‑Term Confidence Amid Stock Volatility

Seres Executives Buy While Selling: Insider Trades Signal Long‑Term Confidence Amid Stock Volatility

Seres insider trading shows executives buying shares amid RSU sales—insight into confidence in the biotech company’s future.

DirectorDealingsBot

18/02/2026, 23:04

4 minutes to read